Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics, Inc. held its 2026 annual meeting on June 2, 2026. Stockholders elected seven directors to serve until the 2027 annual meeting. There were 26,714,337 shares outstanding as of the April 6, 2026 record date, with 22,672,284 shares, or about 85%, present or represented by proxy.
Stockholders approved the Second Amended and Restated 2016 Employee Stock Purchase Plan, which had been adopted by the board on April 2, 2026. They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
A schedule 13G/A amendment reports that FMR LLC (filed as an amendment) beneficially owns 3,188,401 shares of Avalo Therapeutics common stock, representing 6.1% of the class. The filing shows sole voting and sole dispositive power over those shares and lists Abigail P. Johnson in related cover responses.
Avalo Therapeutics director Kevin Robert Lind received a stock option grant covering 20,100 shares of Common Stock. The option has an exercise price of $13.96 per share and expires on June 2, 2036. It vests 100% on the first anniversary of the grant date, subject to his continued board service. Following this award, he holds 20,100 derivative securities directly.
Avalo Therapeutics director Samantha Truex received a new stock option grant, not an open-market share purchase. She was granted options to buy 20,100 shares of Avalo Therapeutics common stock at an exercise price of $13.96 per share. These options vest 100% on the first anniversary of the grant date, contingent on her continued board service, and expire on June 2, 2036. Following this award, she holds 20,100 stock options directly, with no sales or exercises reported in this filing.
Avalo Therapeutics, Inc. director Gilla Kaplan received a grant of stock options linked to the company’s common stock. The award covers 20,100 options with an exercise price of $13.96 per share and expires on June 2, 2036.
According to the terms, the option vests 100% on the first anniversary of the grant date, as long as the director continues to serve through that date. After this grant, Kaplan holds 20,100 stock options directly, giving equity-based, long-term incentive aligned with future company performance.
Avalo Therapeutics director Aaron Kantoff received a new stock option grant as part of his compensation. On the grant date, he was awarded options covering 20,100 shares of Avalo Therapeutics common stock at an exercise price of $13.96 per share. These options vest 100% on the first anniversary of the grant date, as long as he continues serving as a director on that date, and expire on June 2, 2036. After this grant, his total reported stock option holdings from this award are 20,100 options, with no open-market buying or selling involved.
Avalo Therapeutics, Inc. director Michael Thomas Heffernan received a grant of stock options as compensation. He was awarded 29,500 stock options, each giving the right to buy common stock at an exercise price of $13.96 per share. The options vest 100% on the first anniversary of the grant date, provided he continues to serve as a director on that vesting date. After this grant, he holds 29,500 stock options directly, and the options are scheduled to expire on June 2, 2036.
Avalo Therapeutics director Rita Jain received a new stock option grant. The award covers 20,100 options to buy Avalo Therapeutics common stock at an exercise price of $13.96 per share, with all options vesting 100% on the first anniversary of the grant date, subject to her continued board service.
Following this compensation-related grant, Jain holds 20,100 stock options directly, and the options are scheduled to expire on June 2, 2036. The filing does not show any open‑market purchases or sales of Avalo Therapeutics shares, only this option award.
AVTX affiliate filed a Form 144 to report proposed sales and issuances of Common Stock related to option exercises and restricted stock vesting. The notice lists proposed sales or issuances on 06/02/2026, including 16,400, 3,166, 3,167 and 20,100 shares tied to exercises and vesting under registered plans.
The filing names Morgan Stanley Smith Barney LLC Executive Financial Services as the broker and indicates cash transactions for option exercises; additional procedural details and whether shares have already been sold are not shown in the excerpt.
Avalo Therapeutics, Inc.’s Chief Medical Officer, Doyle Mittie, reported an exercise-and-sell stock transaction. On May 28, 2026, she exercised stock options to acquire 679 shares of common stock at $8.04 per share and sold 679 shares in an open-market trade at $16.00 per share.
The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025. Following these trades, she directly holds 47,122 shares of common stock and 118,321 stock options that remain outstanding.